AgaMatrix said today that it brought in a $56 million funding round for the eponymous continuous glucose monitor its WaveForm Technologies subsidiary is developing.

The round, which includes $6 million from new and existing backers and $50 million in senior debt financing from Perceptive Advisors, is slated for paying down debt and increasing production capacity, product development and clinical work for the commercialization of WaveForm’s CGM in Europe and FDA clearance in the U.S., Salem, N.H.-based AgaMatrix said.

Get the full story at our sister site, Drug Delivery Business News